Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

SUMO-1 (human) (CT) polyclonal antibody

 
BML-PW9460-0025 25 µl 108.00 USD
 
BML-PW9460-0100 100 µl 345.00 USD
Do you need bulk/larger quantities?
 

Product Specification

Alternative Name:Sentrin-1, Small ubiquitin-related modifier 1
 
Host:Rabbit
 
Immunogen:Synthetic peptide corresponding to aa 72-97 of human SUMO-1.
 
UniProt ID:P63165
 
Species reactivity:Human
 
Applications:WB
 
Recommended Dilutions/Conditions:Western Blot (1:1,000)
Suggested dilutions/conditions may not be available for all applications.
Optimal conditions must be determined individually for each application.
 
Blocking Peptide:For Blocking peptide see Prod. No. BML-PP9475.
 
Purity Detail:Partially purified by salt precipitation .
 
Formulation:Liquid. In PBS containing 0.01% sodium azide.
 
Shipping:Shipped on Blue Ice
 
Long Term Storage:-20°C
 
Scientific Background:The small ubiquitin-related modifier SUMO-1 belongs to the growing family of ubiquitin-related proteins involved in post-translational protein modification. It is present in all eukaryotic kingdoms and is highly conserved from yeast to humans. Whereas invertebrates have only one SUMO gene, three members of the SUMO family have been described in vertebrates, SUMO-1 and the close homologues SUMO-2 and SUMO-3 with some 50% homology between SUMO-1 and SUMO-2/3. The SUMO family members have a short N-terminal extension that is absent in ubiquitin, and the function of which is unknown and the sequence of which varies between the three family members.  Unlike ubiquitin, SUMO-1 does not appear to target proteins for degradation but seems to be involved in the modulation of protein-protein interactions. Although having only 18% amino acid sequence identity with ubiquitin, the overall structure closely resembles that of ubiquitin. Whereas the two C-terminal glycine residues required for isopeptide bond formation are conserved between the two molecules, Lys48 found in ubiquitin, and required to generate ubiquitin polymers, is substituted by Gln69in SUMO-1 thereby providing an explanation of why SUMO-1 has not been observed to form polymers.  An increasing number of SUMO-1 substrates are being described but three major substrates for SUMO-1 modification are RanGAP1, PML and IκBα proteins. 
 
Technical Info/Product Notes:The antiserum was raised in New Zealand White rabbits to a synthetic peptide corresponding to amino acid residues 72-97 of human SUMO-1. The antibody has been partially purified by salt precipitation and is suspended in PBS containing 0.01% sodium azide as a preservative. BML-PW9460 has been characterised for specificity against various members of the ubiquitin-like protein family including ubiquitin, multi-ubiquitin chains, SUMO2/3, UCRP, Nedd8, and FAT10. This antibody shows no cross-reactivity with any of these Ubl proteins upon Western blotting under the conditions tested.

Reactivity of the antibody with both pro- and mature forms of SUMO-1 is completely abolished by preincubation of the antibody with its cognate peptide (product code BML-PP9475). For Western blot an initial dilution of at least 1:1000 is recommended. BML-PW9460 has not been characterised for use in immunoprecipitation or immunohistochemical applications.
 
BML-PW9460 WB
Western blot analysis: SUMOylation assay utilising SUMO-1, SUMO E1 (BML-UW9330), SUMO E2 (BML-UW9320) and RANGAP1 as substrate in presence (lane 2) and absence (lane 1) of ATP after SDS-PAGE and blotting to PVDF with subsequent probing with BML-PW9460.
Please mouse over
BML-PW9460 WB

Related Products

Blocking peptide for SUMO-1 (human) (CT) pAb (Prod. No. BML-PW9460) 

≥92% (HPLC) | Print as PDF
 
BML-PP9475-0100 100 µg 55.00 USD
Do you need bulk/larger quantities?
 

Related Literature

Brochures
Stem Cells
Stem Cells
Download as PDF

Catalogs
Ubiquitin & UBL Signaling Catalog
Ubiquitin & UBL Signaling Catalog
Download as PDF

All new literature pieces

Recommend this page

 
For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2017 Enzo Life Sciences, Inc.,